Nilotinib (Tasigna) in the Treatment of Early Diffuse Systemic Sclerosis: An Open-Label, Pilot Clinical Trial
Ontology highlight
ABSTRACT: To assess the safety, efficacy, and molecular change associated with treatment of patients with early, diffuse cutaneous systemic sclerosis (dcSSc) with nilotinib (Tasigna™).
ORGANISM(S): Homo sapiens
PROVIDER: GSE65405 | GEO | 2015/08/27
SECONDARY ACCESSION(S): PRJNA273886
REPOSITORIES: GEO
ACCESS DATA